Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema
Main Article Content
Keywords
Cpfe, Combined pulmonary fibrosis and emphysema, Pulmonary fibrosis, lung cancer
Abstract
Background and aim: There are many epidemiological pieces of evidence that show combined pulmonary fibrosis and emphysema (CPFE) patients have an increased risk of lung cancer. We conducted a systematic review of all published data to define the characteristics and treatments of lung cancer that develops in CPFE by performing a meta-analysis.
Methods: Databases(including PubMed, Medline, CNKI, VIP, etc.) were searched to find original articles that related to lung cancer in CPFE(CPFE-LC) patients and a meta-analysis was used to analyze the included 15 articles. Stata17.0 software was performed for this meta-analysis.
Results: Fifteen original studies that assessed 5933 patients were included in this meta-analysis. In the pooled data, people with CPFE-LC were elderly(70.58 years) and heavy smokers( 0.959, 45.793 pack-years), with a male predominance(0.959). Most lung cancer in CPFE was located in the lower lobe(0.533) and obvious areas of pulmonary fibrosis(0.516). Highest prevalence of cellular subtypes of lung cancer in CPFE was squamous carcinoma(SQCC, 0.437) and chemotherapy was the main treatment(0.387). The mortality rate was 0.720(95%CI: 0.657-0.783) and the 5-year survival rate was 0.250(95%CI: 0.133-0.368). The main cause of death was infection(0.268) and respiratory failure was the main cause of death after surgery(0.392).
Conclusions: Lung cancer in CPFE, most commonly SQCC, presents in elderly heavy smokers with a male, located in the lower lobe of the lung and the areas of fibrosis predominance. Chemotherapy is the main treatment and the optimal treatment remains to be explored.
References
2. Cottin V, Nunes H, Brillet P Y, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26(4): 586-93. doi: 10.1183/09031936.05.00021005.
3. Hirano A C G, Targueta E P, Ferraz de Campos F P, et al. Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers. Autops Case Rep. 2017; 7(2): 15-26. doi: 10.4322/acr.2017.022.
4. Cottin V and Cordier J F. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med. 2012; 18(5): 418-27. doi: 10.1097/MCP.0b013e328356803b.
5. Roshan R, Guptal M, Kulshrestha R, Menon B, and Chhabra S K. Combined pulmonary fibrosis and emphysema in a welder. Monaldi Arch Chest Dis. 2012; 77(1): 26-8. doi: 10.4081/monaldi.2012.164.
6. Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology. 2014; 19(2): 239-245. doi: 10.1111/resp.12207.
7. Tokgoz Akyıl F, Sevim T, Akman C, et al. The predictors of mortality in IPF - Does emphysema change the prognosis? Sarcoidosis Vasc Diffuse Lung Dis. 2016; 33(3): 267-274.
8. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009; 136(1): 10-15. doi: 10.1378/chest.08-2306.
9. Lin H and Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis. 2015; 7(4): 767-79. doi: 10.3978/j.issn.2072-1439.2015.04.17.
10. Hage R, Gautschi F, Steinack C, and Schuurmans M M. Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management. Int J Chron Obstruct Pulmon Dis. 2021; 16: 167-177. doi: 10.2147/copd.S286360.
11. Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, and Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology. 2010; 15(2): 265-71. doi: 10.1111/j.1440-1843.2009.01676.x.
12. Fujiwara A, Tsushima K, Sugiyama S, et al. Histological types and localizations of lung cancers in patients with combined pulmonary fibrosis and emphysema. Thorac Cancer. 2013; 4(4): 354-360. doi: 10.1111/1759-7714.12023.
13. Girard N, Marchand-Adam S, Naccache J-M, et al. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients. Journal of Thoracic Oncology. 2014; 9(8): 1162-1170. doi: https://doi.org/10.1097/JTO.0000000000000209.
14. Hata A, Sekine Y, Kota O, Koh E, and Yoshino I. Impact of combined pulmonary fibrosis and emphysema on surgical complications and long-term survival in patients undergoing surgery for non-small-cell lung cancer. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1261-8. doi: 10.2147/copd.S94119.
15. Kim H, Yoo H, Pyo H, et al. Impact Of Underlying Pulmonary Diseases On Treatment Outcomes In Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy. Int J Chron Obstruct Pulmon Dis. 2019; 14: 2273-2281. doi: 10.2147/copd.S210759.
16. Kwak N, Park C M, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014; 108(3): 524-30. doi: 10.1016/j.rmed.2013.11.013.
17. Mimae T, Suzuki K, Tsuboi M, et al. Severity of lung fibrosis affects early surgical outcomes of lung cancer among patients with combined pulmonary fibrosis and emphysema. Medicine (Baltimore). 2016; 95(29): e4314. doi: 10.1097/md.0000000000004314.
18. Minegishi Y, Kokuho N, Miura Y, et al. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer. 2014; 85(2): 258-63. doi: 10.1016/j.lungcan.2014.05.016.
19. Nasim F and Moua T. Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis. ERJ Open Res. 2020; 6(4). doi: 10.1183/23120541.00521-2020.
20. Otsuka H, Sugino K, Hata Y, et al. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema. Mol Clin Oncol. 2016; 5(3): 273-278. doi: 10.3892/mco.2016.954.
21. Ueno F, Kitaguchi Y, Shiina T, et al. The Preoperative Composite Physiologic Index May Predict Mortality in Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema. Respiration. 2017; 94(2): 198-206. doi: 10.1159/000477587.
22. Zhang M, Yoshizawa A, Kawakami S, et al. The histological characteristics and clinical outcomes of lung cancer in patients with combined pulmonary fibrosis and emphysema. Cancer Med. 2016; 5(10): 2721-2730. doi: 10.1002/cam4.858.
23. Kumagai S, Marumo S, Yamanashi K, et al. Prognostic significance of combined pulmonary fibrosis and emphysema in patients with resected non-small-cell lung cancer: a retrospective cohort study. Eur J Cardiothorac Surg. 2014; 46(6): e113-9. doi: 10.1093/ejcts/ezu384.
24. Moon S W, Park M S, Kim Y S, et al. Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation. BMC Pulm Med. 2019; 19(1): 177. doi: 10.1186/s12890-019-0951-2.
25. Oh J Y, Lee Y S, Min K H, et al. Impact and prognosis of lung cancer in patients with combined pulmonary fibrosis and emphysema. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37(4): e2020020. doi: 10.36141/svdld.v37i4.7316.
26. Takenaka T, Furuya K, Yamazaki K, Miura N, Tsutsui K, and Takeo S. The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer. Surg Today. 2018; 48(2): 229-235. doi: 10.1007/s00595-017-1577-8.
27. da Costa Santos C M, de Mattos Pimenta C A, and Nobre M R. The PICO strategy for the research question construction and evidence search. Rev Lat Am Enfermagem. 2007; 15(3): 508-11. doi: 10.1590/s0104-11692007000300023.
28. Koo H J, Do K H, Lee J B, Alblushi S, and Lee S M. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(9): e0161437. doi: 10.1371/journal.pone.0161437.
29. Kitaguchi Y, Fujimoto K, Hotta J, Horie S, Hirayama J, and Hanaoka M. Clinical Characteristics and Predictors of Mortality in Patients with Combined Pulmonary Fibrosis and Emphysema Syndrome and Lung Cancer. J Pulm Respir Med. 2015; 5(3):263. doi: 10.4172/2161-105X.1000263.
30. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002; 165(3): 378-81. doi: 10.1164/ajrccm.165.3.2107134.
31. Xu L, Bian W, Gu X H, and Shen C. Genetic polymorphism in matrix metalloproteinase-9 and transforming growth factor-β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population. Kaohsiung J Med Sci. 2017; 33(3): 124-129. doi: 10.1016/j.kjms.2016.12.004.
32. Hou W, Hu S, Li C, et al. Cigarette Smoke Induced Lung Barrier Dysfunction, EMT, and Tissue Remodeling: A Possible Link between COPD and Lung Cancer. Biomed Res Int. 2019; 2019: 2025636. doi: 10.1155/2019/2025636.
33. Saito A, Horie M, Micke P, and Nagase T. The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2018; 19(11). doi: 10.3390/ijms19113611.
34. Samarelli A V, Masciale V, Aramini B, et al. Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development. Int J Mol Sci. 2021; 22(22). doi: 10.3390/ijms222212179.
35. Greenburg G and Hay E D. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol. 1982; 95(1): 333-9. doi: 10.1083/jcb.95.1.333.
36. Mahmood M Q, Sohal S S, Shukla S D, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1515-24. doi: 10.2147/copd.S81032.
37. Caliò A, Lever V, Rossi A, et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology. 2017; 71(5): 725-735. doi: 10.1111/his.13269.
38. Gao L, Xie S, Liu H, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema revisited with the 2015 World Health Organization classification of lung tumors. Clin Respir J. 2018; 12(2): 652-658. doi: 10.1111/crj.12575.
39. Bauml J M, Mick R, Ciunci C, et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. 2019; 5(9): 1283-1290. doi: 10.1001/jamaoncol.2019.1449.
40. Theelen W, Peulen H M U, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9): 1276-1282. doi: 10.1001/jamaoncol.2019.1478.
41. Schmid U, Liesenfeld K H, Fleury A, Dallinger C, and Freiwald M. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemother Pharmacol. 2018; 81(1): 89-101. doi: 10.1007/s00280-017-3452-0.
42. Yamanaka T, Harimoto N, Yokobori T, et al. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer. 2020; 122(7): 986-994. doi: 10.1038/s41416-020-0744-7.
43. Kato R, Haratani K, Hayashi H, et al. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Br J Cancer. 2021; 124(5): 914-924. doi: 10.1038/s41416-020-01201-z.
44. Usui K, Tanai C, Tanaka Y, Noda H, and Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011; 16(2): 326-31. doi: 10.1111/j.1440-1843.2010.01907.x.
45. Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015; 45(10): 1263-70. doi: 10.1007/s00595-014-1071-5.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
